Contact

The iPSC-first CDMO 

Making cell therapies mainstream.

GMP Manufacturing services & platforms for iPSC-derived allogeneic cell therapies and regenerative medicines

Scientist on cell lab

Pursuing an immune oncology or cell regenerative medicine cell therapy? Start here.

As CDMO focusing on iPSC-derived allogeneic cell therapies, we offer cell line development, process development, GMP manufacturing platforms and QC testing.

Cellistic is ready right now to help you de-risk and accelerate the development and manufacture of your therapeutic program — especially if you’re looking to serve a much larger market than is possible with an autologous or donor-derived allogeneic approach.

If you’ve got a breakthrough idea

we can guide you step-by-step through every part of development and manufacturing.

If you need tech transfer

we have the processes and analytical methods in place – and the experience on-hand – to optimize or scale to your exact specifications.

If you’re looking for a CDMO to develop or optimize your manufacturing process

our pre-established platforms and enabling technologies offer an efficient, proven way to maintain your momentum.
CELL Entry point diagram_NEW
Artboard 1 1

Talk to the iPSC-first CDMO.

See how Cellistic can remove the scientific, operational, and economic barriers to scalable patient delivery. And, over time, help ensure the use of extraordinary therapies becomes a very ordinary thing.

Artboard 1 1

The CDMO that can take your cell therapy mainstream.

Cellistic integrates the services, platforms, and expertise required to enable successful iPSC-derived allogeneic cell therapy GMP manufacturing – and we’re continually expanding our capabilities with a single purpose in mind: to help you limit risk, accelerate time to clinic, and reduce costs.


Puzzle Icon

Platforms + Technologies

Pulse™ Platform for iPSC cell line development and Cellistic Echo Platform for scalable GMP manufacturing that put your program on a faster track

Vials Icon

CDMO  Services

Full-spectrum services tuned to your program’s distinct needs and deployed to streamline its progress

Cell Types Icon

Cell Types 

Broad, deep expertise in (iPSC-derived) cell types that removes the uncertainties of harnessing their full potential

We are here: The point of Cellistic’s difference.

Other cell therapy manufacturers may offer iPSC platforms or development services, but only Cellistic provides a truly integrated solution, built on a singular iPSC focus, ensuring programs transition seamlessly from discovery to GMP without reinventing the process.

Working_Icons-2

Focus & Expertise

Since day one, we have maintained a singular focus on iPSCs. Every investment we make and every experience we build directly strengthens our core, delivering greater value to you.

Turn the promise of your program into a reality.

Whether you’re pursuing an autologous cell therapy or already have an iPSC-based project underway, Cellistic offers a practical and proven path forward for your cell therapy or regenerative medicine — making it possible to turn a high-potential idea into a viable therapeutic faster and more efficiently.

Group 35264
iPSC-Derived Allogeneic Autologous Donor-Derived Allogeneic
Your opportunity

Transfer an existing process to a flexible, full-scale, iPSC-focused CDMO

Go from one-to-one to one-to-many using our proven platforms

Overcome limitations to increase scale, consistency, quality, and characterization

Purpose-built to deliver on iPSC potential.

Our headquarters in Mont-Saint-Guibert, Belgium, is home to the first EMA-certified and FDA and PMDA compliant purpose-built iPSC cell therapy GMP manufacturing facility.

With all capabilities in a single location, our clients collaborate closely with our multidisciplinary team, with everyone aligned on the shared goal: developing and manufacturing iPSC-based allogeneic cell therapies as efficiently and cost-effectively as possible.

lab-collection

How can we help propel your cell therapy?

Let’s start with what’s on your mind – your project plans, your questions about iPSC technology, your most pressing scientific and business drivers. We’re here to listen and, if we’re a good fit, to help you maximize the opportunity and value of your cell therapy.